摘要
目的研究生长激素联合胸腺肽α1对重症肺炎患者血清高迁移率族蛋白1(HMGB1)、miR-155、白细胞介素(IL)-17A及APACHE-Ⅱ评分的影响。方法研究对象为该院于2016年1月至2017年1月期间收治的120例重症肺炎患者为研究对象,随机分组为对照组和试验组,每组患者60例,在基础治疗基础上,试验组患者联合注射用胸腺肽α1和生长激素治疗,对照组仅采用生长激素治疗,两组患者均治疗2周。对比两组患者的治疗效果、APACHEⅡ和CPIS评分、血气指标、肺功能、炎性指标恢复时间、血清HMGB1、miR-155、不良反应之间的差异。结果治疗效果,试验组患者的总有效率(85.00%)明显高于对照组(46.67%);两组患者的APACHEⅡ、CPIS评分、PaCO 2、TNF-α、IL-17A、IL-10、IL-22、血清HMGB1、miR-155水平、炎性指标恢复时间均显著下降(P<0.05),且试验组患者的APACHEⅡ、CPIS评分、PaCO 2、肿瘤坏死因子α(TNF-α)、IL-17A、IL-10、IL-22、血清HMGB1、miR-155水平、炎性指标恢复时间均显著低于对照组(P<0.05);两组患者的PaO 2、SpO 2、FVC、FEV1、FEV1/FVC均显著提高(P<0.05),且试验组患者的PaO 2、SpO 2、FVC、FEV1、FEV1/FVC高于对照组(P<0.05)。不良反应,两组不良反应无统计学意义。结论生长激素联合胸腺肽α1治疗重症肺炎患者的效果明显,可能是通过降低患者机体中HMGB1、miR-155及炎症因子的水平来发挥作用的。
Objective To study the effect of growth hormone combined with thymosinα1 on serum high mobility group protein 1(HMGB1),miR-155,IL-17A and Apache-Ⅱin patients with severe pneumonia.Methods 120 patients with severe pneumonia admitted in our hospital from January 2016 to January 2017 were randomly divided into control group and experimental group,60 patients in each group.On the basis of basic treatment,patients in experimental group were treated with thymosinα1 and growth hormone,while patients in control group were only treated with growth hormone,and patients in both groups were treated for 2 weeks.The therapeutic effect,ApacheⅡand CPIs scores,blood gas index,pulmonary function,inflammatory index recovery time,serum HMGB1,miR-155 and adverse reactions were compared between the two groups.Results The total effective rate of the experimental group(85.00%)was significantly higher than that of the control group(46.67%);the ApacheⅡ,CPIs scores,PaCO 2,TNF-α,IL-17A,IL-10,IL-22,serum HMGB1,miR-155 levels and the recovery time of inflammatory indicators were significantly reduced in the two groups(P<0.05),and the ApacheⅡ,CPIs scores,PaCO 2,TNF-α,IL-17A,IL-10,IL-22,the serum levels of HMGB1,miR-155 and the recovery time of inflammatory indicators in serum were significantly lower than those in the control group(P<0.05);PaO 2,SpO 2,FVC,FEV1,FEV1/FVC in the two groups were significantly higher(P<0.05),and PaO 2,SpO 2,FVC,FEV1,FEV1/FVC in the experimental group were higher than those in the control group(P<0.05).The adverse reactions of the two groups were not statistically significant.Conclusion The effect of growth hormone combined with thymosinα1 in the treatment of severe pneumonia is obvious,which may play a role by reducing the levels of HMGB1,miR-155 and inflammatory factors.
作者
齐亚丽
姚瑶
李婷
QI Yali;YAO Yao;LI Ting(Department of Respiratory and Critical Care Medicine,People′s Hospital of Qinghai Province,Xining,Qinghai 810000,China;Heart Function Examination Room,No.1 Department of Cardiology,People′s Hospital of Qinghai Province,Xining,Qinghai 810000,China)
出处
《国际检验医学杂志》
CAS
2019年第23期2900-2904,共5页
International Journal of Laboratory Medicine
